Within the PAM signaling pathway, PI3K is a primary drug target for cancer treatment since its hyperactivity is strongly associated with tumor progression, enhanced tumor microvascular formation, and increased cancer cell invasiveness (Liu et al., 2020a). This evidence concerns the gene PIK3CB and neoplasm.